{"pmid":32348165,"title":"Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","text":["Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.","The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.","Health Secur","Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan","32348165"],"abstract":["The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines."],"journal":"Health Secur","authors":["Billington, John","Deschamps, Isabelle","Erck, Stanley C","Gerberding, Julie L","Hanon, Emmanuel","Ivol, Sabrina","Shiver, John W","Spencer, Julia A","Van Hoof, Johan"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348165","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1089/hs.2020.0043","keywords":["covid-19","epidemic management/response","infectious diseases","sars-cov-2","vaccine development"],"topics":["Treatment"],"weight":1,"_version_":1666138495425445888,"score":9.490897,"similar":[{"pmid":32238177,"pmcid":"PMC7112750","title":"Emerging infectious diseases and outbreaks: implications for women's reproductive health and rights in resource-poor settings.","text":["Emerging infectious diseases and outbreaks: implications for women's reproductive health and rights in resource-poor settings.","This century is witnessing dramatic changes in the health needs of the world's populations. The double burden of infectious and chronic diseases constitutes major causes of morbidity and mortality. Over the last two decades, there has been a rise in infectious diseases, including the severe acute respiratory syndrome virus (SARS), the H1N1 pandemic influenza, the Ebolavirus and the Covid-19 virus. These diseases have rapidly spread across the world and have reminded us of the unprecedented connectivity that defines our modern civilization. Though some countries have made substantial progress toward improving global surveillance for emerging infectious diseases (EIDs), the vast majority of Low-and Middle-income Countries (LMICs) with fragile health systems and various system-related bottlenecks remain vulnerable to outbreaks and, as such, experience dramatic social and economic consequences when they are reported. Lessons learned from past outbreaks suggest that gender inequalities are common across a range of health issues relating to Sexual and Reproductive Health and Rights (SRHR), with women being particularly disadvantaged, partially due to the burden placed on them. Though these countries are striving to improve their health systems and be more inclusive to this vulnerable group, the national/ global outbreaks have burdened the overall system and thus paralyzed normal services dedicated to the delivery of Sexual and Reproductive Health (SRH) services. In this paper, we discuss the global commitments to SRH, the impact of the EIDs on the LMICs, the failure in the delivery of SRH services, and the strategies for successful implementation of recovery plans that must address the specific and differentiated needs of women and girls in resource-poor settings.","Reprod Health","Chattu, Vijay Kumar","Yaya, Sanni","32238177"],"abstract":["This century is witnessing dramatic changes in the health needs of the world's populations. The double burden of infectious and chronic diseases constitutes major causes of morbidity and mortality. Over the last two decades, there has been a rise in infectious diseases, including the severe acute respiratory syndrome virus (SARS), the H1N1 pandemic influenza, the Ebolavirus and the Covid-19 virus. These diseases have rapidly spread across the world and have reminded us of the unprecedented connectivity that defines our modern civilization. Though some countries have made substantial progress toward improving global surveillance for emerging infectious diseases (EIDs), the vast majority of Low-and Middle-income Countries (LMICs) with fragile health systems and various system-related bottlenecks remain vulnerable to outbreaks and, as such, experience dramatic social and economic consequences when they are reported. Lessons learned from past outbreaks suggest that gender inequalities are common across a range of health issues relating to Sexual and Reproductive Health and Rights (SRHR), with women being particularly disadvantaged, partially due to the burden placed on them. Though these countries are striving to improve their health systems and be more inclusive to this vulnerable group, the national/ global outbreaks have burdened the overall system and thus paralyzed normal services dedicated to the delivery of Sexual and Reproductive Health (SRH) services. In this paper, we discuss the global commitments to SRH, the impact of the EIDs on the LMICs, the failure in the delivery of SRH services, and the strategies for successful implementation of recovery plans that must address the specific and differentiated needs of women and girls in resource-poor settings."],"journal":"Reprod Health","authors":["Chattu, Vijay Kumar","Yaya, Sanni"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238177","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1186/s12978-020-0899-y","keywords":["covid-19","ebola","emerging and re-emerging infectious diseases (eids)","gender","low- and middle-income countries (lmics)","sars","sexual and reproductive health and rights (srhrs)","sustainable developmental goals (sdgs)","women","zika"],"locations":["Ebolavirus"],"weight":0,"_version_":1666138490449952768,"score":332.80017},{"pmid":32418794,"title":"A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.","text":["A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.","The UK Government recognised the importance of vaccines in the control of new emerging disease threats and in 2015 established the UK Vaccine Network to focus on specific areas of need. One of these was the understanding of what is involved in the development of a new vaccine and what are the potential bottlenecks to a rapid response in the face of an epidemic such as Ebola, MERS and more recently COVID-19. A Working Group was established to initially produce a Vaccine Development Process Map for a Human Vaccine. However, in view of the importance of animal wellbeing and the significant impact of diseases with Zoonotic potential, a similar Map has been created outlining the Veterinary Vaccine Development Process. This paper describes the production of that Map and covers the process from the generation of a Target Product Profile (TPP) through Discovery and Feasibility, and on to Product Development and Registration.","Vaccine","Francis, Michael James","32418794"],"abstract":["The UK Government recognised the importance of vaccines in the control of new emerging disease threats and in 2015 established the UK Vaccine Network to focus on specific areas of need. One of these was the understanding of what is involved in the development of a new vaccine and what are the potential bottlenecks to a rapid response in the face of an epidemic such as Ebola, MERS and more recently COVID-19. A Working Group was established to initially produce a Vaccine Development Process Map for a Human Vaccine. However, in view of the importance of animal wellbeing and the significant impact of diseases with Zoonotic potential, a similar Map has been created outlining the Veterinary Vaccine Development Process. This paper describes the production of that Map and covers the process from the generation of a Target Product Profile (TPP) through Discovery and Feasibility, and on to Product Development and Registration."],"journal":"Vaccine","authors":["Francis, Michael James"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418794","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.vaccine.2020.05.007","keywords":["efficacy","quality","registration","safety","vaccine development","veterinary vaccine"],"topics":["Treatment"],"weight":1,"_version_":1667159284596604928,"score":329.8175},{"pmid":32192278,"title":"WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.","text":["WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.","To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners.","Epidemiol Health","Jee, Youngmee","32192278"],"abstract":["To discuss whether the coronavirus disease 2019 (COVID-19) outbreak constitutes a Public Health Emergency of International Concern (PHEIC), World Health Organization (WHO) organized the 15-member International Health Regulations Emergency Committee (EC). On January 22-23 and January 30, 2020, EC convened and discussed whether the situation in China and other countries would constitute PHEIC and issued recommendations for WHO, China and the international community. Based on the recommendations of EC, WHO declared the COVID-19 outbreak a PHEIC. One of the purposes of the declaration of PHEIC was to alarm countries with weak public health infrastructures to prepare promptly for emerging infectious diseases (EID) and provide WHO with a framework for proactively supporting those countries. On February 3, 2020, WHO proposed the 2019 COVID-19 Strategic Preparedness and Response Plan, which includes accelerating research and development (R&D) processes as one of three major strategies. On February 11-12, 2020, WHO held the Global Research and Innovation Forum: Towards a Research Roadmap for COVID-19. The fact that a COVID-19 R&D forum was the first meeting convened after the PHEIC declaration testifies to the importance of R&D in response to EID. Korea has demonstrated a remarkable capacity in its laboratory response by conducting high-throughput COVID-19 testing and utilizing innovative drive-through samplings. These measures for early detection and screening of cases should be followed by full efforts to produce research-based evidence by thoroughly analyzing epidemiological, clinical and immunological data, which will facilitate the development of vaccines and therapeutics for COVID-19. It is expected that Korea plays a global partner for COVID-19 research by actively participating in immediate and mid/long-term priorities jointly led by WHO and global partners."],"journal":"Epidemiol Health","authors":["Jee, Youngmee"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192278","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.4178/epih.e2020013","keywords":["covid-19","emergency committee","international health regulations","public health emergency of international concern","research and development"],"locations":["China","China","South Korea","South Korea"],"countries":["China","Korea, Republic of"],"countries_codes":["CHN|China","KOR|Korea, Republic of"],"weight":0,"_version_":1666138490002210816,"score":319.4446},{"pmid":32420652,"title":"A nursing informatics response to COVID-19: perspectives from five regions of the world.","text":["A nursing informatics response to COVID-19: perspectives from five regions of the world.","The 21st century has seen several infectious disease outbreaks that have turned into epidemics and pandemics including Severe Acute Respiratory Syndrome (SARS) which began in Asia in 2003 (Poon, Guan, Nicholls, Yuen, & Peiris, 2004), followed by H1N1 that emerged in Mexico and the United States in 2009 (Belongia et al., 2010). Next came the lesser known Middle East Respiratory Syndrome (MERS) originating in Saudi Arabia in 2012 (Assiri et al., 2013), after which the Ebola outbreak in West Africa took place from 2014 to 2016, with a more recent occurrence in the Democratic Republic of Congo from 2018 to 2019 (Malvy, McElroy, de Clerck, Gunther, & van Griensven, 2019). To date, the coronavirus (COVID-19) outbreak that started in Wuhan, in the Hubei province of China, in late December 2019 seems to be eclipsing all of these previous infectious diseases in terms of its global reach and impact (Wang, Horby, Hayden, & Gao, 2020). After being declared by the World Health Organization (WHO) as a public health emergency on 30 January 2020 (World Health Organization, 2020c), it was elevated to a pandemic status on 11 March 2020 (World Health Organization, 2020d). As of 28 April 2020, there are more than 2.9 million cases and 202,597 deaths reported worldwide (World Health Organization, 2020b).","J Adv Nurs","Atique, Suleman","Bautista, John Robert","Block, Lorraine J","Lee, Jay Jung Jae","Lozada-Perezmitre, Erika","Nibber, Raji","O'Connor, Siobhan","Peltonen, Laura-Maria","Ronquillo, Charlene","Tayaben, Jude","Thilo, Friederike J S","Topaz, Maxim","32420652"],"abstract":["The 21st century has seen several infectious disease outbreaks that have turned into epidemics and pandemics including Severe Acute Respiratory Syndrome (SARS) which began in Asia in 2003 (Poon, Guan, Nicholls, Yuen, & Peiris, 2004), followed by H1N1 that emerged in Mexico and the United States in 2009 (Belongia et al., 2010). Next came the lesser known Middle East Respiratory Syndrome (MERS) originating in Saudi Arabia in 2012 (Assiri et al., 2013), after which the Ebola outbreak in West Africa took place from 2014 to 2016, with a more recent occurrence in the Democratic Republic of Congo from 2018 to 2019 (Malvy, McElroy, de Clerck, Gunther, & van Griensven, 2019). To date, the coronavirus (COVID-19) outbreak that started in Wuhan, in the Hubei province of China, in late December 2019 seems to be eclipsing all of these previous infectious diseases in terms of its global reach and impact (Wang, Horby, Hayden, & Gao, 2020). After being declared by the World Health Organization (WHO) as a public health emergency on 30 January 2020 (World Health Organization, 2020c), it was elevated to a pandemic status on 11 March 2020 (World Health Organization, 2020d). As of 28 April 2020, there are more than 2.9 million cases and 202,597 deaths reported worldwide (World Health Organization, 2020b)."],"journal":"J Adv Nurs","authors":["Atique, Suleman","Bautista, John Robert","Block, Lorraine J","Lee, Jay Jung Jae","Lozada-Perezmitre, Erika","Nibber, Raji","O'Connor, Siobhan","Peltonen, Laura-Maria","Ronquillo, Charlene","Tayaben, Jude","Thilo, Friederike J S","Topaz, Maxim"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420652","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jan.14417","locations":["Nicholls","Mexico","United States","Saudi Arabia","West Africa","McElroy","Wuhan","Hubei","China","Horby","Hayden"],"countries":["Saudi Arabia","China","Mexico","United States"],"countries_codes":["SAU|Saudi Arabia","CHN|China","MEX|Mexico","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1667159284487553025,"score":241.07745},{"pmid":32259480,"pmcid":"PMC7136867","title":"SARS-CoV-2 Vaccines: Status Report.","text":["SARS-CoV-2 Vaccines: Status Report.","SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.","Immunity","Amanat, Fatima","Krammer, Florian","32259480"],"abstract":["SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population."],"journal":"Immunity","authors":["Amanat, Fatima","Krammer, Florian"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259480","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.immuni.2020.03.007","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493105995779,"score":238.87222}]}